Anne Horgan
Partner @ Cambridge Innovation Capital
Paris, France
Anne Horgan is a Partner at Cambridge Innovation Capital.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Anne Horgan invests in
Stages Anne Horgan invests in
Countries Anne Horgan invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 2 (67%)
- Biotechnology 2 (67%)
- Banking 1 (33%)
- Aerospace 1 (33%)
- GreenTech 1 (33%)
Stage
- Series A 2 (67%)
- Private Equity 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Complement Therapeutics operates as a preclinical stage company. Complement Therapeutics develops a precision medicine diagnostic platform allowing it to stratify patients based on their complement-activation profile with the potential to enable both patient selection and serving as an efficacy biomarker in future clinical studies. | $78.7M / Series A / Apr 17, 2023 | ||
| Mosaic Therapeutics is an oncology therapeutics company that develops targeted combination therapies for cancer patients. The company utilizes a proprietary platform to identify synergistic drug combinations based on biomarker-defined patient populations, aiming to improve the efficacy and durability of responses. Mosaic Therapeutics' researchfocuses on identifying specific biomarkers that can be targeted with tailored drug combinations, enhancing the effectiveness of treatments for individual patients. | $28M / Series A / Apr 04, 2023 | ||
| Botanical Ventures Limited is a privately held company based in London, United Kingdom, and has been incorporated since 2017. The company brings together a diverse range of industries — including financial services, asset tokenization, mining operations, real estate, biotechnology, and botanical ventures — with a focus on building real-world valuethrough innovation and cross-sector expertise.Co-founded by Alexander Thomas Dover and Nicolas-André Borel, Botanical Ventures Limited operates with a vision to connect traditional industries with emerging technologies. While Alexander leads the company’s strategic direction, Nicolas-André serves as Chief Operating Officer, playing a key role in driving operational growth and cross-border initiatives.Registered under UK company law, Botanical Ventures is committed to long-term, sustainable development and creating new opportunities across both established and frontier markets. | $5.5M / Private Equity / Feb 10, 2022 |
Co-Investors
Cambridge Innovation Capital (CIC) is a leading venture capital firm specialising in early-stage deep technology and life sciences companies. The firm is headquartered in Cambridge, England, and currently has approximately £600 million assets under management. The firm has a twelve-year track record of investing in science-driven companies, with a portfolio spanning cancer therapies, genomic diagnostics, surgical robotics, artificial intelligence, semiconductors and quantum computing. Portfolio companies have collectively raised over £3.2 billion and created more than 2,750 jobs during CIC's period of investment, and four portfolio companies have reached unicorn status. Founded in 2013, CIC is a preferred investor for the University of Cambridge, operating under a long-standing collaboration agreement that provides the team with privileged access to the most promising investment opportunities emerging from the University.
Cambridge Innovation Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Anne Horgan
Partner
|
|||
Damian Crowther
Entrepreneur In Residence
|
|||
Edward Benthall
Chairman
|
|||
Humphrey Battcock
Independent Non-executive Director
|
|||
Ian Jauncey
Operating Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Anne Horgan invest in?
Anne Horgan invests primarily in Medical, Biotechnology and Banking startups, most often at Series A and Private Equity stage. Most of the 3 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Anne Horgan?
Public channels for Anne Horgan include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Anne Horgan last invest?
The most recent investment recorded for Anne Horgan closed in Apr 2023. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
